Pomerantz LLP has filed a class action lawsuit against Babcock & Wilcox Enterprises, Inc. on behalf of investors who bought securities between November 5, 2025, and March 11, 2026. The lawsuit alleges losses suffered by these investors, potentially due to securities fraud or corporate misconduct. Investors who believe they were affected are encouraged to contact Pomerantz LLP to join the case. This legal action highlights ongoing scrutiny of corporate practices impacting shareholder value.
The class action lawsuit involving Babcock & Wilcox Enterprises, Inc. provides context for readers interested in industrial stocks. For readers following Industrials, here is Pluang's market snapshot as of Oct 21, 2026 02:31 WIB: out of 135 priced US Industrials stocks, 89 rose and 46 fell. Notable movers include Mueller Industries Inc. (MLI) at USD 56.61 with a 1-day change of -6.95% and 100% buy order activity, Eos Energy Enterprises Inc. (EOSE) at USD 1.71 with a 1-day change of -5.80% and 69% buy orders, and 3M Company (MMM) at USD 170.53 with a 1-day gain of +5.21% and 97% buy orders.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
